Alessio Amatu
Alessio Amatu
Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
Email verificata su ospedaleniguarda.it
TitoloCitata daAnno
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795, 2015
5392015
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ...
Cancer discovery 3 (6), 658-673, 2013
4532013
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of …
A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ...
The Lancet Oncology 17 (6), 738-746, 2016
3402016
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)
A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Cancer discovery 7 (4), 400-409, 2017
2332017
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ...
Science translational medicine 6 (224), 224ra26-224ra26, 2014
2022014
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
A Amatu, A Sartore-Bianchi, S Siena
ESMO open 1 (2), e000023, 2016
1362016
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ...
Annals of oncology 26 (10), 2092-2097, 2015
1062015
Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer
A Amatu, A Sartore-Bianchi, C Moutinho, A Belotti, K Bencardino, ...
Clinical cancer research 19 (8), 2265-2272, 2013
872013
Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer
A Sartore-Bianchi, E Ardini, R Bosotti, A Amatu, E Valtorta, A Somaschini, ...
JNCI: Journal of the National Cancer Institute 108 (1), 2016
742016
Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.
S Siena, A Sartore-Bianchi, S Lonardi, L Trusolino, C Martino, ...
Journal of Clinical Oncology 33 (15_suppl), 3508-3508, 2015
742015
Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?
A Amatu, K Bencardino, A Sartore-Bianchi, S Siena
Annals of translational medicine 1 (2), 2013
722013
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer
L Barault, A Amatu, FE Bleeker, C Moutinho, C Falcomata, V Fiano, ...
Annals of oncology 26 (9), 1994-1999, 2015
712015
OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma
G Poggi, A Amatu, B Montagna, P Quaretti, C Minoia, C Sottani, L Villani, ...
Cardiovascular and interventional radiology 32 (6), 1187-1192, 2009
642009
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 …
F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ...
Cancer 122 (4), 574-581, 2016
592016
Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors
G Poggi, P Quaretti, C Minoia, G Bernardo, MR Bonora, R Gaggeri, ...
Anticancer research 28 (6B), 3835-3842, 2008
572008
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer
L Barault, A Amatu, G Siravegna, A Ponzetti, S Moran, A Cassingena, ...
Gut 67 (11), 1995-2005, 2018
542018
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer
A Sartore-Bianchi, K Bencardino, A Cassingena, F Venturini, C Funaioli, ...
Cancer treatment reviews 36, S1-S5, 2010
422010
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
A Amatu, A Somaschini, G Cerea, R Bosotti, E Valtorta, P Buonandi, ...
British journal of cancer 113 (12), 1730, 2015
392015
Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: a systematic review and meta-analysis
F Tosi, E Magni, A Amatu, G Mauri, K Bencardino, M Truini, S Veronese, ...
Clinical colorectal cancer 16 (3), e153-e163, 2017
332017
Complications of percutaneous radiofrequency thermal ablation of primary and secondary lesions of the liver
G Poggi, A Riccardi, P Quaretti, C Teragni, A Delmonte, A Amatu, G Saini, ...
Anticancer research 27 (4C), 2911-2916, 2007
302007
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20